## [Freyr 3D Series · Orphan Drugs in Latin America: A Strategic Look at Mexico, Brazil, and Colombia. Part 3 – Colombia: Between Regulatory Progress and Sustainability Challenges](/blog/freyr-3d-series-orphan-drugs-in-latin-america-a-strategic-look-at-mexico-brazil-and-colombia-part-3-colombia-between-regulatory-progress-and-sustainability-challenges) October 10, 2025 ![Freyr 3D Series · Orphan Drugs in Latin America: A Strategic Look at Mexico, Brazil, and Colombia. Part 3 – Colombia: Between Regulatory Progress and Sustainability Challenges]() 3 min read - [Medicinal Products](/blog-main-categories/medicinal-products) - [Regulatory Affairs](/blog-main-categories/regulatory-affairs) [Spanish](/blog/freyr-3d-series-medicamentos-huerfanos-en-america-latina-una-mirada-estrategica-a-mexico-brasil-y-colombia-parte-3-colombia-entre-el-avance-normativo-y-los-retos-de-sostenibilidad) The third and final entry of the **Freyr 3D Series \| Orphan Drugs in LATAM** explores the landscape in **Colombia**. After reviewing the experiences of Mexico and Brazil, we close this trilogy with a country that built an **early and solid legal framework**, yet still faces the challenge of maintaining **long-term access** to these high-cost therapies. ## Regulatory Framework in Colombia - **Decree 481 of 2004**, with which Colombia took its first steps in recognizing medicines with **low commercial availability**. This decree regulated so-called **Medicamentos Vitales No Disponibles (MVND)** —indispensable life-saving products that, due to low profitability, are not found in the local market or are not available in sufficient quantities. Although this figure does **not** correspond normatively to **orphan drugs**, it set a precedent by establishing **differentiated access mechanisms** for hard-to-procure cases. - The true turning point came with **Law 1392 of 2010**, which expressly recognized **orphan diseases in Colombia**, declared them a matter of national interest, and established the State’s obligation to ensure diagnosis, treatment, and patient registry. - Two years later, **Law 1438 of 2011** reinforced this vision by explicitly including **orphan drugs** within health benefits plans. This framework made Colombia an early reference point in the region, although legal strength alone does not remove the **economic and operational challenges** that condition real patient access. ## Access Mechanisms and Requirements - **MVND (Decree 481 of 2004):** allows importation under a **simplified pathway**, **without ordinary marketing authorization**, the country’s main exceptional access route. - **Full marketing authorization (Decree 677 of 1995):** **orphan drugs in Colombia** must follow the complete registration route, with the option of **prioritization** when they have a high public-health impact. - **INVIMA technical requirements:** dossier in **CTD format**, **post-marketing pharmacovigilance** plans, and **labeling/information materials** aligned with current regulations. ## Technical Requirements The process for **orphan drugs in Colombia** is demanding and is articulated through **INVIMA**: - **CTD dossier** with quality, safety, and efficacy data. - **Clinical and preclinical evidence**, often limited by low disease prevalence, is contextualized to the local setting. - **Post-marketing pharmacovigilance plans**, mandatory to monitor safety and effectiveness in real-world practice. - **Traceability and patient registries**, key to supporting regulatory and financing decisions. - **Labeling and information materials** adapted to current standards. Although there are differentiated mechanisms such as the MVND regime, the route for **orphan drugs** requires **anticipatory preparation** that combines international dossiers with local requirements and robust follow-up systems. ## Challenges The **Colombian regulatory framework** has been a pioneer in the region, but its implementation faces structural barriers: - **High therapy costs** which strain the sustainability of the health system. - **Limited clinical evidence**, which makes regulatory dossiers harder to substantiate. - **Dependence on imports** exposes the country to logistical delays and supply issues. - **Reimbursement and coverage hurdles** that can generate inequities in access. - **The need to strengthen traceability and patient registries**, to generate local data that backs regulatory and public-health decisions. In short, the challenge is no longer mainly normative, but **economic and operational**: ensuring that the legal framework translates into **sustainable, continuous access**. In the regional context, **Mexico** has prioritized **fast-track** and reliance mechanisms; **Brazil** relies on incorporation into the **SUS**; while **Colombia** established a **robust legal framework** that recognizes **orphan diseases** as a national priority. The challenge now is to ensure that rights guarantee go hand in hand with a financing model. ## Role of an Expert Partner In an environment with so many opportunities and risks, having a specialized partner is decisive. **Freyr LATAM** supports companies in the **adaptation of international dossiers to INVIMA**, in **anticipating regulatory risks**, in the **design of robust pharmacovigilance plans**, and in building **sustainable access strategies**. The combination of **global expertise and local presence** enables Freyr to shorten approval timelines and reduce risks, while helping companies position themselves as responsible actors in a highly sensitive market. **Explore how your company can turn regulatory complexity into a clear pathway to access in Colombia**[**. Let’s discuss how to anticipate your strategy together.**](https://qr.pro/i/p/684c71ec3a7b5)